Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Utility of the ultrasound examination of the hand and wrist joints in the management of established rheumatoid arthritis.

Ceponis A, Onishi M, Bluestein HG, Kalunian K, Townsend J, Kavanaugh A.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):236-44. doi: 10.1002/acr.22119.

2.

Improving knowledge in palliative medicine with a required hospice rotation for third-year medical students.

Porter-Williamson K, von Gunten CF, Garman K, Herbst L, Bluestein HG, Evans W.

Acad Med. 2004 Aug;79(8):777-82.

PMID:
15277135
3.

Reduction in circulating dsDNA antibody titer after administration of LJP 394.

Weisman MH, Bluestein HG, Berner CM, de Haan HA.

J Rheumatol. 1997 Feb;24(2):314-8.

PMID:
9034989
4.

Neuropsychiatric disease in Sjögren's syndrome: anti-ribosomal P and anti-neuronal antibodies.

Spezialetti R, Bluestein HG, Peter JB, Alexander EL.

Am J Med. 1993 Aug;95(2):153-60.

PMID:
8356981
5.

BEN, a novel surface molecule of the immunoglobulin superfamily on avian hemopoietic progenitor cells shared with neural cells.

Corbel C, Cormier F, Pourquie O, Bluestein HG.

Exp Cell Res. 1992 Nov;203(1):91-9.

PMID:
1426054
6.

An antigen expressed by avian neuronal cells is also expressed by activated T lymphocytes.

Corbel C, Bluestein HG, Pourquie O, Vaigot P, Le Douarin NM.

Cell Immunol. 1992 Apr 15;141(1):99-110.

PMID:
1372844
7.

Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus.

Papero PH, Bluestein HG, White P, Lipnick RN.

Clin Exp Rheumatol. 1990 Jul-Aug;8(4):417-24.

PMID:
2397630
8.
9.

Anatomic and genetic considerations in the pathogenesis of ankylosing spondylitis.

Bluestein HG.

J Rheumatol Suppl. 1988 Sep;16:29-32. Review.

PMID:
3057208
10.

Generation of human cytomegalovirus-specific cytotoxic T-lymphocytes in a short-term culture.

Laubscher A, Bluestein HG, Spector SA, Zvaifler NJ.

J Immunol Methods. 1988 May 25;110(1):69-77.

PMID:
2836515
13.

Neuropsychiatric manifestations of systemic lupus erythematosus.

Bluestein HG.

N Engl J Med. 1987 Jul 30;317(5):309-11. No abstract available.

PMID:
3600721
14.

Polymorphism of lymphocyte function-associated antigen-1 demonstrated by a lupus patient's alloantiserum.

Pischel KD, Marlin SD, Springer TA, Woods VL Jr, Bluestein HG.

J Clin Invest. 1987 Jun;79(6):1607-14.

15.

Use of the monoclonal antibody 12F1 to characterize the differentiation antigen VLA-2.

Pischel KD, Hemler ME, Huang C, Bluestein HG, Woods VL Jr.

J Immunol. 1987 Jan 1;138(1):226-33.

PMID:
3023488
16.
17.

Very late activation antigens (VLA) are human leukocyte-neuronal crossreactive cell surface antigens.

Pischel KD, Bluestein HG, Woods VL Jr.

J Exp Med. 1986 Aug 1;164(2):393-406.

18.

Vancomycin-induced vasculitis.

Markman M, Lim HW, Bluestein HG.

South Med J. 1986 Mar;79(3):382-3.

PMID:
2937155
19.

Deoxy-ATP accumulation in adenosine deaminase-inhibited human B and T lymphocytes.

Gruber HE, Cohen AH, Firestein GS, Redelman D, Bluestein HG.

Adv Exp Med Biol. 1986;195 Pt A:503-7. No abstract available.

PMID:
3487921
20.

Immunopathogenesis of the neuropsychiatric manifestations of systemic lupus erythematosus.

Bluestein HG, Pischel KD, Woods VL Jr.

Springer Semin Immunopathol. 1986;9(2-3):237-49. Review. No abstract available.

PMID:
3027907
22.

The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.

Albert D, Bluestein HG, Thompson L, Seegmiller JE.

Cell Immunol. 1984 Jul;86(2):510-7.

PMID:
6610485
23.

The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of purine-nucleoside phosphorylase deficiency.

Albert D, Bluestein HG, Willis RC, Nette K, Seegmiller JE.

Cell Immunol. 1984 Jul;86(2):501-9.

PMID:
6428752
24.

Deoxyadenosine (AdR) inhibition of newly activated lymphocytes: blockade at the G0-G1 interface.

Redelman D, Bluestein HG, Cohen AH, Depper JM, Wormsley S.

J Immunol. 1984 Apr;132(4):2030-8.

PMID:
6421932
25.
26.
27.

Epstein-Barr virus and rheumatoid arthritis.

Bluestein HG, Hasler F.

Surv Immunol Res. 1984;3(1):70-7. No abstract available.

PMID:
6326237
28.

DNA synthesis inhibitors block protein synthesis in the human lymphocyte.

Albert DA, Bluestein HG.

Int J Immunopharmacol. 1984;6(2):147-53.

PMID:
6203850
30.

Antibodies reactive with central nervous system antigens.

Bluestein HG, Zvaifler NJ.

Hum Pathol. 1983 May;14(5):424-8.

PMID:
6132871
32.

The pathogenesis of central nervous system manifestations of systemic lupus erythematosus.

Zvaifler NJ, Bluestein HG.

Arthritis Rheum. 1982 Jul;25(7):862-6. No abstract available.

PMID:
7104058
33.

Antineuronal antibodies in systemic lupus erythematosus.

Bluestein HG, Woods VL Jr.

Arthritis Rheum. 1982 Jul;25(7):773-8. No abstract available.

PMID:
7104053
34.

Oropharyngeal Epstein-Barr virus excretion in rheumatoid arthritis.

Depper JM, Zvaifler NJ, Bluestein HG.

Arthritis Rheum. 1982 Apr;25(4):427-31.

PMID:
6280734
35.
36.

Procainamide-lymphocyte reactions. A possible explanation for drug-induced autoimmunity.

Bluestein HG, Redelman D, Zvaifler NJ.

Arthritis Rheum. 1981 Aug;24(8):1019-23. No abstract available.

PMID:
6169349
37.
38.

Brain-reactive lymphocytotoxic antibody in the cerebrospinal fluid of patients with systemic lupus erythematosus: correlation with central nervous system involvement.

Williams GW, Bluestein HG, Steinberg AD.

Clin Immunol Immunopathol. 1981 Jan;18(1):126-32. No abstract available.

PMID:
7460395
39.

Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells.

Bardwick PA, Bluestein HG, Zvaifler NJ, Depper JM, Seegmiller JE.

Arthritis Rheum. 1980 Jun;23(6):626-32. No abstract available.

PMID:
6248075
40.

Altered deoxynucleoside triphosphate levels paralleling deoxyadenosine toxicity in adenosine deaminase inhibited human lymphocytes.

Bluestein HG, Thompson LF, Albert DA, Seegmiller JE.

Adv Exp Med Biol. 1980;122A:427-31. No abstract available.

PMID:
6968502
41.

Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome.

Bluestein HG, Zvaifler NJ, Weisman MH, Shapiro RF.

Lancet. 1979 Oct 20;2(8147):816-9.

PMID:
90917
42.

Antibody-mediated suppression of antibody-dependent cytotoxic effector cell function.

Zvaifler NJ, Bluestein HG.

Clin Immunol Immunopathol. 1979 Jul;13(3):277-86. No abstract available.

PMID:
88291
43.
44.

Lymphocyte reactivity of antisera to cryoproteins in systemic lupus erythematosus.

Klippel JH, Bluestein HG, Zvaifler NJ.

Clin Immunol Immunopathol. 1979 Jan;12(1):52-61. No abstract available.

PMID:
570468
45.
46.
47.

Neoantigen of the membrane attack complex of human complement: Occurrence on peripheral blood leukocytes from patients with systemic lupus erythematosus.

Curd JG, Sundsmo JS, Kolb WP, Bluestein HG, Müller-Eberhard HJ.

Arthritis Rheum. 1978 Mar;21(2):177-82.

PMID:
76471
48.

Accumulation of deoxyribonucleotides as a possible mediator of immunosuppression in hereditary deficiency of adenosine deaminase.

Bluestein HG, Willis RC, Thompson LF, Matsumoto S, Seegmiller JE.

Trans Assoc Am Physicians. 1978;91:394-402. No abstract available.

PMID:
314193
49.

Antibody-mediated suppression of bone marrow colony formation in vitro.

Meyer-Hamme S, Bluestein HG.

J Cell Physiol. 1978 Jan;94(1):47-56.

PMID:
304065
50.

Lymphocytotoxic antibody activity in cryoprecipitates from serum of patients with SLE.

Zvaifler NJ, Bluestein HG.

Arthritis Rheum. 1976 Sep-Oct;19(5):844-50.

PMID:
1085625

Supplemental Content

Loading ...
Support Center